Evelo touts PhII win for in­flam­ma­tion pro­gram; In­novent, An­Heart claim in­ter­im PhII suc­cess in NSCLC

Flag­ship’s Evelo Bio­sciences is tout­ing a win Mon­day in a Phase II study ex­am­in­ing an oral treat­ment for in­flam­ma­to­ry dis­eases.

Re­searchers saw a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion for the ex­per­i­men­tal drug EDP1815 in the Pso­ri­a­sis Area and Sever­i­ty In­dex (PASI) score com­pared to place­bo af­ter 16 weeks, Evelo an­nounced Mon­day. The pro­gram is in clin­i­cal de­vel­op­ment for a wide range of in­flam­ma­to­ry dis­eases such as pso­ri­a­sis, atopic der­mati­tis and Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER